Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Early Detection of Cognitive Dysfunction in Diabetes

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2012 by Wuhan General Hospital of Guangzhou Military Command.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
zhipeng xu, Wuhan General Hospital of Guangzhou Military Command
ClinicalTrials.gov Identifier:
NCT01830998
First received: April 1, 2013
Last updated: April 10, 2013
Last verified: January 2012
  Purpose

The rate of cognitive decline due to ageing is increased 1.5-fold to 2.0-fold in individuals with type 2 diabetes.There are no established specific treatment measures to prevent or ameliorate cognitive impairments in patients with diabetes. we want to detecte early clinical dementia in diabete.


Condition
Dementia
Olfactory Function

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Study of Cognitive Dysfunction and Diabetes

Resource links provided by NLM:


Further study details as provided by Wuhan General Hospital of Guangzhou Military Command:

Primary Outcome Measures:
  • MMSE Olfactory function dementia [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
    MMSE,Olfactory function and PET(fMRI) were observed.


Biospecimen Retention:   None Retained

serum


Estimated Enrollment: 400
Study Start Date: January 2012
Estimated Study Completion Date: January 2014
Estimated Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts
control,MCI, Olfactory dsfunction
There are different groups:control,MCI, Olfactory dsfunction.
control, MCI
control and MCI group.Glycaemic control
control and MCI
treatment and without treatment
MCI and Olfactory function
observation between MCI and Olfactory function groups.

Detailed Description:

Clinically relevant cognitive decrements in relation to diabetes mainly occur during two crucial periods in life: the period of brain development in childhood, and the period when the brain undergoes neurodegenerative changes associated with ageing.Potential leads for treatment are to optimise glycaemic control and avoid and treat vascular risk factors.we want to detecte early clinical dementia in diabete by MMSE and Olfactory function.

  Eligibility

Ages Eligible for Study:   50 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Patients with type 2 diabetes

Criteria

Inclusion Criteria:

  • Patients with type 2 diabetes(Age>50 years)

Exclusion Criteria:

  • with stroke or other complications.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01830998

Contacts
Contact: xuzhipeng Wuqiang lihonghua, doctor 13871168392 21823074@qq.com

Locations
China, Hubei
tongji Medical University Enrolling by invitation
Wuhan, Hubei, China, 430074
Wuhan general hospital of Guangzhou Command Recruiting
Wuhan, Hubei, China, 430070
Contact: xu zhi peng, doctor    13871168392    xzhp14@sohu.com   
Wuhan general hospital of Guangzhou command Active, not recruiting
Wuhan,chongqing, Hubei, China, 430070
Sponsors and Collaborators
Wuhan General Hospital of Guangzhou Military Command
  More Information

No publications provided

Responsible Party: zhipeng xu, doctor, Wuhan General Hospital of Guangzhou Military Command
ClinicalTrials.gov Identifier: NCT01830998     History of Changes
Other Study ID Numbers: 20130401
Study First Received: April 1, 2013
Last Updated: April 10, 2013
Health Authority: China: Food and Drug Administration

Keywords provided by Wuhan General Hospital of Guangzhou Military Command:
Dementia
Olfactory

Additional relevant MeSH terms:
Cognition Disorders
Dementia
Brain Diseases
Central Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Nervous System Diseases

ClinicalTrials.gov processed this record on November 24, 2014